title: Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation: a single-center experience.
abstract: OBJECTIVE
  Corticosteroids have been considered the mainstay of immunosuppressive therapy after liver transplantation. However, the side effects of long-term steroid use such as diabetes, infections, and bone disease, including growth retardation in children, are serious problems. Our immunosuppression regimen includes FK506 and steroid withdrawal by 30 days after transplantation. The aim of this study was to determine the outcomes of liver transplant, using this immunosuppressive regimen.
  
  
  METHODS
  Fifteen primary liver transplant recipients were performed between January 1994 and May 2003 and data were reviewed retrospectively. Eight pediatric and four adult recipients, who had survived more than 3 months after transplantation, were included in this sample. The immunosuppressive regimen consisted of FK 506 (Prograf), initially at doses of 0.03 mg/kg, with dose adjustments to achieve daily trough levels of approximately 10 to 12 ng/mL, and predonisone, initially at 4 mg/kg/d, with a taper and cessation by 30 days when the graft was stable.
  
  
  RESULTS
  All recipients were successfully withdrawn by 30 days. Acute rejection episodes occurred in three patients, no patient was diagnosed with chronic rejection. The acute rejection-free rate at 5 year was 74.1%. No recipient had diabetes, serious infections or bone disease.
  
  
  CONCLUSIONS
  Our primary immunosuppressive regimen of rapid steroid withdrawal is safe with regard to acute and chronic rejection with benefits upon steroid-related side effects.
authors.affiliation: Department of Surgery, Hirosaki University School of Medicine, Hirosaki, Japan. ytoyoki@cc.hirosaki-u.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Toyoki
authors.forename: K
authors.initials: K
authors.lastname: Hakamada
authors.forename: S
authors.initials: S
authors.lastname: Narumi
authors.forename: E
authors.initials: E
authors.lastname: Totsuka
authors.forename: M
authors.initials: M
authors.lastname: Nara
authors.forename: H
authors.initials: H
authors.lastname: Ono
authors.forename: Y
authors.initials: Y
authors.lastname: Ishizawa
authors.forename: M
authors.initials: M
authors.lastname: Sasaki
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D002675:Child, Preschool; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005190:Family; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D016031:Liver Transplantation / Q000502:physiology* / Q000706:statistics & numerical data; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D016559:Tacrolimus